Clinical and MRI measures to identify non-acute MOG-antibody disease in adults
Brain · 2023
DOI: 10.1093/brain/awac480 ↗Kurz gefasst
Fachartikel in der Zeitschrift Brain, 2023. Verfasst von Rosa Cortese und 47 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Surgery and Neuroscience, University of Siena, Siena, Italy. Hauptthemen laut MEDLINE: Neuromyelitis Optica, Multiple Sclerosis. Die Arbeit wurde bisher 41-mal zitiert (Crossref) und nennt 37 Literaturangaben. Gefördert von: ECTRIMS.
Abstract (Originalsprache)
MRI and clinical features of myelin oligodendrocyte glycoprotein (MOG)-antibody disease may overlap with those of other inflammatory demyelinating conditions posing diagnostic challenges, especially in non-acute phases and when serologic testing for MOG antibodies is unavailable or shows uncertain results. We aimed to identify MRI and clinical markers that differentiate non-acute MOG-antibody disease from aquaporin 4 (AQP4)-antibody neuromyelitis optica spectrum disorder and relapsing remitting multiple sclerosis, guiding in the identification of patients with MOG-antibody disease in clinical practice. In this cross-sectional retrospective study, data from 16 MAGNIMS centres were included. Data collection and analyses were conducted from 2019 to 2021. Inclusion criteria were: diagnosis of MOG-antibody disease; AQP4-neuromyelitis optica spectrum disorder and multiple sclerosis; brain and cord MRI at least 6 months from relapse; and Expanded Disability Status Scale (EDSS) score on the day of MRI. Brain white matter T2 lesions, T1-hypointense lesions, cortical and cord lesions were identified. Random forest models were constructed to classify patients as MOG-antibody disease/AQP4-neuromyelitis optica spectrum disorder/multiple sclerosis; a leave one out cross-validation procedure assessed the performance of the models. Based on the best discriminators between diseases, we proposed a guide to target investigations for MOG-antibody disease. One hundred and sixty-two patients with MOG-antibody disease [99 females, mean age: 41 (±14) years, median EDSS: 2 (0–7.5)], 162 with AQP4-neuromyelitis optica spectrum disorder [132 females, mean age: 51 (±14) years, median EDSS: 3.5 (0–8)], 189 with multiple sclerosis (132 females, mean age: 40 (±10) years, median EDSS: 2 (0–8)] and 152 healthy controls (91 females) were studied. In young patients (<34 years), with low disability (EDSS < 3), the absence of Dawson’s fingers, temporal lobe lesions and longitudinally extensive lesions in the cervical cord pointed towards a diagnosis of MOG-antibody disease instead of the other two diseases (accuracy: 76%, sensitivity: 81%, specificity: 84%, P < 0.001). In these non-acute patients, the number of brain lesions < 6 predicted MOG-antibody disease versus multiple sclerosis (accuracy: 83%, sensitivity: 82%, specificity: 83%, P < 0.001). An EDSS < 3 and the absence of longitudinally extensive lesions in the cervical cord predicted MOG-antibody disease versus AQP4-neuromyelitis optica spectrum disorder (accuracy: 76%, sensitivity: 89%, specificity: 62%, P < 0.001). A workflow with sequential tests and supporting features is proposed to guide better identification of patients with MOG-antibody disease. Adult patients with non-acute MOG-antibody disease showed distinctive clinical and MRI features when compared to AQP4-neuromyelitis optica spectrum disorder and multiple sclerosis. A careful inspection of the morphology of brain and cord lesions together with clinical information can guide further analyses towards the diagnosis of MOG-antibody disease in clinical practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Surgery and Neuroscience, University of Siena, Siena, Italy.
- NMR Research Unit, Queen Square MS Centre, Department of Neuroinflammation, Faculty of Brain Sciences, UCL Queen Square Institute of Neurology, University College London, London, UK.
- Center for Medical Imaging Computing, Medical Physics and Biomedical Engineering, UCL, London, UK.
- Universitat Oberta de Catalunya, Barcelona, Spain.
- NMO Clinical Service at the Walton Centre, Liverpool, UK.
- Department of Neurology, Cleveland Clinic, AbuDhabi, UAE.
ORCID-Profile: Rosa Cortese, Ferran Prados, Douglas Kazutoshi Sato, Massimo Filippi, Maria Assunta Rocca, Alex Rovira, Jaume Sastre-Garriga, Georgina Arrambide, Matthias Grothe, Ruth Schneider, Anne-Katrin Proebstel, Bruno Stankoff
Förderung
- ECTRIMS
Zitieren
APA
Cortese, R., Battaglini, M., Prados, F., Bianchi, A., Haider, L., Jacob, A., Palace, J., Messina, S., Paul, F., Wuerfel, J., Marignier, R., Durand-Dubief, F., de Medeiros Rimkus, C., Callegaro, D., Sato, D. K., Filippi, M., Rocca, M. A., Cacciaguerra, L., Rovira, A., …, & MAGNIMS Study Group (2023). Clinical and MRI measures to identify non-acute MOG-antibody disease in adults. Brain. https://doi.org/10.1093/brain/awac480
Vancouver
Cortese R, Battaglini M, Prados F, Bianchi A, Haider L, Jacob A, et al. Clinical and MRI measures to identify non-acute MOG-antibody disease in adults. Brain. 2023. doi:10.1093/brain/awac480
BibTeX
@article{Cortese2023,
author = {Cortese, Rosa and Battaglini, Marco and Prados, Ferran and Bianchi, Alessia and Haider, Lukas and Jacob, Anu and Palace, Jacqueline and Messina, Silvia and Paul, Friedemann and Wuerfel, Jens and Marignier, Romain and Durand-Dubief, Françoise and de Medeiros Rimkus, Carolina and Callegaro, Dagoberto and Sato, Douglas Kazutoshi and Filippi, Massimo and Rocca, Maria Assunta and Cacciaguerra, Laura and Rovira, Alex and Sastre-Garriga, Jaume and Arrambide, Georgina and Liu, Yaou and Duan, Yunyun and Gasperini, Claudio and Tortorella, Carla and Ruggieri, Serena and Amato, Maria Pia and Ulivelli, Monica and Groppa, Sergiu and Grothe, Matthias and Llufriu, Sara and Sepulveda, Maria and Lukas, Carsten and Bellenberg, Barbara and Schneider, Ruth and Sowa, Piotr and Celius, Elisabeth G and Proebstel, Anne-Katrin and Yaldizli, Özgür and Müller, Jannis and Stankoff, Bruno and Bodini, Benedetta and Carmisciano, Luca and Sormani, Maria Pia and Barkhof, Frederik and De Stefano, Nicola and Ciccarelli, Olga and MAGNIMS Study Group, MAGNIMS Study Group},
title = {Clinical and MRI measures to identify non-acute MOG-antibody disease in adults},
journal = {Brain},
year = {2023},
doi = {10.1093/brain/awac480}
}
EUVIMED